← back to search

Judith Bushong

Bristol-Myers Squibb (United States) · GB
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, and Colorectal Cancer Treatments and Studies.
h-index
11
citations
1,097
works
22
NIH funding
primary concept
Medicine
email

Recent publications

Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Nature Medicine 2023cited by 156position: middledoi
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology 2023cited by 71position: middledoi
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816
ESMO Open 2023cited by 15position: middledoi
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology 2022cited by 369position: middledoi
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology 2021cited by 322position: middledoi
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
Journal of Clinical Oncology 2021cited by 37position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Tudor–Eliade Ciuleanu · Iuliu Hațieganu University of Medicine and Pharmacy2 papers (2021–2022)Adam Płużański · National Institute of Oncology2 papers (2021–2022)Hossein Borghaei · The Ohio State University2 papers (2021–2022)Julie R. Brahmer · Bloomberg (United States)2 papers (2021–2022)Kenneth J. O’Byrne · Queensland University of Technology2 papers (2021–2022)Luis Paz‐Ares · Zhejiang Cancer Hospital2 papers (2021–2022)László Urbán · University of Debrecen2 papers (2021–2022)Martin Reck · St. Luke's Clinic2 papers (2021–2022)Makoto Nishio · Japanese Foundation For Cancer Research2 papers (2021–2022)Suresh S. Ramalingam · Emory University2 papers (2021–2022)Jong-Seok Lee · Korea Advanced Institute of Science and Technology2 papers (2021–2022)Laura J. Eccles · Bristol-Myers Squibb (United States)1 papers (2022–2022)Clarisse Audigier-Valette · Université de Toulon1 papers (2022–2022)Jinhua Cai · Central South University1 papers (2023–2023)Shun Lü · Central South University1 papers (2023–2023)Adam J. Schoenfeld · Hartford Financial Services (United States)1 papers (2022–2022)Joel Sunshine · Johns Hopkins University1 papers (2023–2023)Robert A. Anders · University of Baltimore1 papers (2023–2023)Mauricio Mahave · Samsung Medical Center1 papers (2022–2022) · 1 papers (2023–2023)